Reversible pulmonary arterial hypertension associated with dasatinib for chronic myeloid leukemia

Cancer Research and Treatment

Volumn 47, Issue 4, 2015, Pages 937-942

  Hong, Ji Hyung ^a   Lee, Sung Eun ^a   Choi, Soo Young ^a   Kim, Soo Hyun ^a   Jang, Eun Jung ^a   Bang, Ju Hee ^a   Park, Jin Eok ^a   Jeon, Hye Rim ^a   Oh, Yun Jeong ^a   Yi, Jeong Eun ^a   Jung, Hae Ok ^a   Youn, Ho Joong ^a   Kim, Dong Wook ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Chronic myeloid leukemia; Dasatinib; Pulmonary arterial hypertension

Indexed keywords

ALPHA INTERFERON; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DASATINIB; DIURETIC AGENT; FUROSEMIDE; IMATINIB; NILOTINIB; PONATINIB; PREDNISOLONE; SILDENAFIL; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; VASODILATOR AGENT;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER ECHOCARDIOGRAPHY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAPHY; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; HYPERBILIRUBINEMIA; LOW DRUG DOSE; LUNG CONGESTION; MALE; MIDDLE AGED; PERICARDIAL EFFUSION; PLEURA EFFUSION; PULMONARY HYPERTENSION; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; CHEMICALLY INDUCED; HYPERTENSION, PULMONARY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;

ADULT; ANTIHYPERTENSIVE AGENTS; ANTINEOPLASTIC AGENTS; CALCIUM CHANNEL BLOCKERS; DASATINIB; DIURETICS; HUMANS; HYPERTENSION, PULMONARY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; SILDENAFIL CITRATE; VASODILATOR AGENTS;

EID: 84946718225     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2013.155     Document Type: Article

References (15)

1. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30: 2493-537.
2. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173:1023-30.
3. Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E, Rosenkranz S. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J. 2011;38:218-20.
4. Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res. 2009;33:861-4.
5. Orlandi EM, Rocca B, Pazzano AS, Ghio S. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res. 2012;36:e4-6.
6. Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant. 2009;43:967-8.
7. Sano M, Saotome M, Urushida T, Katoh H, Satoh H, Ohnishi K , et al. Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia: critical alert. Intern Med. 2012;51:2337-40.
8. Hennigs JK, Keller G, Baumann HJ, Honecker F, Kluge S, Bokemeyer C, et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med. 2011;11:30.
9. Montani D, Bergot E, Gunther S, Savale L, Bergeron A, Bourdin A, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125:2128-37.
10. Balasubramaniam V, Le Cras TD, Ivy DD, Grover TR, Kinsella JP, Abman SH. Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol. 2003;284: L826-33.
11. Perros F, Montani D, Dorfmuller P, Durand-Gasselin I, Tcherakian C, Le Pavec J, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;178:81-8.
12. Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med. 2010;182:1171-7.
13. Pullamsetti SS, Berghausen EM, Dabral S, Tretyn A, Butrous E, Savai R, et al. Role of Src tyrosine kinases in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2012;32:1354-65.
14. Quintas-Cardama A, Kantarjian H, O'Brien S, Borthakur G, Bruzzi J, Munden R, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25:3908-14.
15. Kim D, Goh HG, Kim SH, Cho BS, Kim DW. Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy. Int J Hematol. 2011;94:361-71.